Analysis of the TROPiCS-02 trial revealed that therapeutic response to SG was achieved in patients with breast cancer with both low or high TROP2 (assessed by immunohistochemistry [IHC]),11 but most of the aforementioned studies failed to stratify patients by TROP2 level. The gene discussed is TACSTD2; the disease is breast carcinoma.